Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Monash University | OTHER |
| Hudson Institute of Medical Research | UNKNOWN |
| Liggins Institute | OTHER |
| Starship Children's Hospital of New Zealand |
Not provided
Not provided
Not provided
A phase 2 randomised, three-arm, parallel-group, dose-ranging trial to determine safety, efficacy and optimal dosing of intravenous anakinra in premature neonates, with subcutaneous pharmacokinetic sub-study.
Advances in neonatal intensive care have significantly improved the survival rates for extremely premature neonates. Despite this, many survivors develop chronic conditions such as cerebral palsy and chronic lung disease, primarily due to the pro-inflammatory environment common in these patients. Efforts to reduce these conditions using anti-inflammatory glucocorticoids are effective but are hindered by significant adverse effects that outweigh potential benefits for most neonates.
Crucially, not only is inflammation an important driver of morbidities of prematurity, but as shown by the investigators and other research groups, the potent pro-inflammatory cytokine interleukin-1 is a key player.
A phase I/IIa trial of anakinra in extremely premature infants (24 - 27+6 weeks gestational age) demonstrated feasibility of administration intravenous over the first 3 weeks of life, without any acute safety concerns and confirmation of mechanistic pharmacokinetic predictions.
The aims of this phase II dose-ranging trial (Anakinra Pilot 2, AP2) are to:
The primary outcome is to refine understanding of anakinra population pharmacokinetics in extremely premature neonates, and at 3 different dosing levels, to allow determination of optimal dose for population target concentration attainment in future trials.
In addition, the pharmacokinetics of subcutaneously administered anakinra in extremely premature neonates (from week 3) will be explored. Population pharmacokinetic model development and validation, for intravenous and subcutaneous anakinra in premature neonates over the first 3 weeks of life, to enable dose determination for target concentration attainment.
Model performance and validation will be based on metrics and graphics of model 'goodness-of-fit', precision of parameter estimates (relative standard error & confidence intervals for CL, Vd and Ka) and predictive performance and robustness, per published (PMID: 27884052) and regulatory guidance (FDA guidance on Population Pharmacokinetics (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/population-pharmacokinetics).
Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling will also enable exploratory investigation of the relationship between anakinra dose, concentration-time course in blood, and drug effects, both biomarkers of inflammation and clinical endpoints.
AP2 will recruit 24 infants born 24-28 weeks-GA, randomised to one of 3 dosing arms, 8 infants/arm, stratified to ensure balanced GA-distribution. Participants will otherwise receive standard care.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Anakinra dose 1 IV | Active Comparator | Anakinra IV for 21 days |
|
| Anakinra dose 1 IV/SC | Active Comparator | Anakinra IV for 14 days & SC for 7 days |
|
| Anakinra dose 2 IV | Active Comparator | Anakinra IV for 21 days |
|
| Anakinra dose 2 IV/SC | Active Comparator | Anakinra IV for 14 days & SC for 7 days |
|
| Anakinra dose 3 IV | Active Comparator | Anakinra IV for 21 days |
|
| Anakinra dose 3 IV/SC | Active Comparator | Anakinra IV for 14 days & SC for 7 days |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anakinra (Kineret®) | Drug | Standard care plus Anakinra for 21 days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Population Pharmacokinetics (PopPK) Model of the Clearance of anakinra in extremely premature neonates from birth, during the 3-week treatment period. | Point Estimate of Population Total Clearance (CL) of anakinra will be reported. | From Baseline up to Day 21 |
| Population Pharmacokinetics (PopPK) Model of the Volume of Distribution of anakinra in extremely premature neonates from birth, during the 3-week treatment period. | Point Estimate of Population Volume of Distribution (VD) of anakinra will be reported. | From Baseline up to Day 21 |
| Population Pharmacokinetics (PopPK) Model of the Absorption of Population of subcutaneously administered anakinra in extremely premature neonates from birth, during the 3-week treatment period. | Point Estimate of Population Absorption of subcutaneously administered anakinra will be reported. | Day 14-21 |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of bronchopulmonary dysplasia | Early efficacy endpoints (exploratory): incidence of bronchopulmonary dysplasia, in comparison to contemporary unit and national statistics. | 4 months. |
| Hammersmith infant neurological examination |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility of 3 weeks of anakinra administration to extremely premature neonates from birth, both intravenously and subcutaneously. | Feasibility of anakinra IV and SC in premature neonates, at 3 dosing levels, measured as succesful completion of intervention treatment course, including subcutaneous dosing. | 1 month |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Marcel F Nold, Prof | Contact | +61385723936 | marcel.nold@monash.edu | |
| Claudia Nold, Prof | Contact | +61385723936 | claudia.nold@hudson.org.au |
| Name | Affiliation | Role |
|---|---|---|
| Marcel F Nold, Prof | Monash Health/ Monash University/ Hudson Institute of Medical Research | Principal Investigator |
| Claudia Nold, Prof | Hudson Institute of Medical Research | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Monash Children's Hospital | Recruiting | Clayton | Victoria | 3168 | Australia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D047928 | Premature Birth |
| D007249 | Inflammation |
| D001997 | Bronchopulmonary Dysplasia |
| ID | Term |
|---|---|
| D007752 | Obstetric Labor, Premature |
| D007744 | Obstetric Labor Complications |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
| ID | Term |
|---|---|
| D053590 | Interleukin 1 Receptor Antagonist Protein |
| ID | Term |
|---|---|
| D016207 | Cytokines |
| D036341 | Intercellular Signaling Peptides and Proteins |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided
| UNKNOWN |
AP2 is a randomised, three-arm, parallel-group, dose-ranging trial to determine safety, efficacy and optimal dosing of intravenous anakinra in premature neonates, with subcutaneous pharmacokinetic sub-study. Neonates will be randomly assigned to 1 of 3 dosing levels (8 per group), with half of each dosing level assigned to recieve subcutaneous dosing in week 3.
Population pharmacokinetic and physiology-based pharmacokinetic modelling will be employed to build on pharmacokinetic analysis from AP1, including multiple dose levels and subcutaneous dosing. Pooling of pharmacokinetic data from AP1 and AP2 (total n = 48) will enable establishment of a pharmacokinetic model, including key pharmacokinetic parameters clearance (CL), volume of distribution (VD), and absorption rate (Ka, subcutaneous) with sufficient precision (based on relative standard error) and model performance. In addition, PK will be linked through modelling with biomarkers and outcomes in expoloratory PKPD analysis.
Not provided
Not provided
Not provided
Not provided
Early efficacy endpoint (exploratory): Hammersmith infant neurological examination; performed at 3-4 months of corrected age, in comparison to contemporary unit and national statistics.
| 6 months |
| Incidence of intracranial/intraventricular haemorrhage and peri-ventricular leukomalacia. | Early efficacy endpoint (exploratory): incidence of intracranial/intraventricular haemorrhage and peri-ventricular leukomalacia, in comparison to contemporary unit and national statistics. | 4 months |
| Safety of anakinra in extremely premature neonates. | Safety of anakinra IV and SC in premature neonates, at 3 dosing levels, measured as incidence of safety endpoints in particular late-onset sepsis and necrotizing enterocolitis (compared with contemporary unit and national statistics) as well as neutropenia, thrombocytopenia, acute kidney injury, drug-induced liver injury (per Hy's Law). | 4 weeks |
| Individual Total Clearance (CL) of anakinra in extremely premature neonates. | Average of individual model-derived estimates of CL will be reported. | From Baseline up to Day 21. |
| Individual Volume of Distribution (VD) of anakinra in extremely premature neonates. | Average of individual model-derived estimates of VD will be reported. | Baseline to Day 21. |
| Individual Absorption Rate Constant (Ka) of subcutaneously administered anakinra in extremely premature neonates. | Average of individual model-derived estimates of Ka will be reported. | Day 14-21. |
| Individual Maximum Serum Concentration (Cmax) of anakinra. | Average of individual model-derived estimates of Cmax will be reported. | Baseline to Day 21. |
| Individual Area Under the Concentration-time Curve Within a Dosing Interval (AUCtau) of anakinra. | Average of individual model-derived estimates of AUCtau will be reported. | Baseline to D21. |
| Individual Model - derived Ctrough Concentrations of anakinra. | Average of individual model-derived Ctrough concentrations of anakinra will be reported. | Baseline to D21. |
| Influence of anakinra on microbiome. |
Monitoring for lung and gut microbiome changes during the treatment course by collection and analysis of bronchoalveolar lavage fluid (in intubated infants), nasopharyngeal swabs, and stool. |
| 3 weeks |
| Pharmacokinetic (PK)/Pharmacodynamic (PD) Model of the Effect of anakinra Systemic Exposure on clinical endpoints. | Point Estimate of population IC50 of anakinra associated with a reduction in incidence of early efficacy endpoints (exploratory), including bronchopulmonary dysplasia, intracranial/intraventricular haemorrhage & peri-ventricular leukomalacia, and Hammersmith infant neurological examination; performed at 3-4 months of corrected age. | 4 months |
| Pharmacokinetic (PK)/Pharmacodynamic (PD) Model of the Effect of anakinra Systemic Exposure on biomarkers of the inflammatory cascade. | Point Estimate of population IC50 of anakinra, i.e. the drug concentration required to produce 50% of maximal inhibition of the IL-1-driven inflammatory cascade. Biomarkers investigated will include cellular proteomic biomarkers of inflammatory activity and inhibition, including lymphoid and myeloid cell polarisation and activation as well as responsiveness to stimulants such as lipopolysaccharide (LPS) and PMA/ionomycin during the treatment course. | 4 Months. |
| Pharmacokinetic (PK)/Pharmacodynamic (PD) Model of the Effect of anakinra Systemic Exposure on adverse effects. | Point Estimate of population EC50 of anakinra, i.e. the drug concentration associated with exploratory safety endpoints including late-onset sepsis, necrotizing enterocolitis, neutropenia, thrombocytopenia, acute kidney injury, drug-induced liver injury (per Hy's Law). | Baseline to Day 21. |
| Rod Hunt, Prof | Monash Health / Monash University | Principal Investigator |
| Robert Galinsky, Dr | Hudson Institute of Medical Research | Principal Investigator |
| Gergely Toldi, Dr | Starship Children's Hospital / Liggins Institute | Principal Investigator |
| Carl Kirkpatrick, Prof | Monash University | Principal Investigator |
| David Metz, Dr | Monash Health / Royal Children's Hospital | Principal Investigator |
| Starship Children's Hospital | Not yet recruiting | Grafton | Auckland | 1023 | New Zealand |
|
| D000091642 | Urogenital Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D055397 | Ventilator-Induced Lung Injury |
| D055370 | Lung Injury |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D007235 | Infant, Premature, Diseases |
| D007232 | Infant, Newborn, Diseases |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D011506 | Proteins |
| D001685 | Biological Factors |